Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study. A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the ...

7 Phesgo® – a subcutaneous fixed-dose combination of Perjeta and Herceptin – is also approved in more than 120 countries/regions and provides faster and more flexible administration of Perjeta and ...

91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, 95% CI: 0.69-1.00, ...

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

Roche has had time to defend Herceptin against biosimilars, however. A patent-protected subcutaneous formulation of the drug was launched some years ago, and now represents 50% or more of the market.

[10] O'Shaughnessy J, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A ...

Herceptin SC is given as a subcutaneous injection (under the skin) over 2 to 5 minutes every three weeks. More instructions can be found in Section 4. How do I use Herceptin SC? in the full CMI.

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Trastuzumab is a type of targeted cancer drug called a monoclonal ... You usually have injections under the skin (subcutaneous injection) into the stomach, thigh or top of your arm. You might have ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulve ...